Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice.
Poxvirus-based active immunotherapies mediate anti-tumor efficacy by triggering broad and durable Th1 dominated T cell responses against the tumor. While monotherapy significantly delays tumor growth, it often does not lead to complete tumor regression. It was hypothesized that the induced robust in...
Main Authors: | Susan P Foy, Barbara Sennino, Tracy dela Cruz, Joseph J Cote, Evan J Gordon, Felicia Kemp, Veronica Xavier, Alex Franzusoff, Ryan B Rountree, Stefanie J Mandl |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4765931?pdf=render |
Similar Items
-
LAG-3: a very singular immune checkpoint
by: Lui, Y, et al.
Published: (2018) -
Recombinant Poxvirus and the Tumor Microenvironment: Oncolysis, Immune Regulation and Immunization
by: Daniel W. Sharp, et al.
Published: (2016-08-01) -
Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer
by: An-Ping Shi, et al.
Published: (2022-01-01) -
DNA-Sensing Antiviral Innate Immunity in Poxvirus Infection
by: Yue Lu, et al.
Published: (2020-08-01) -
Polymorphisms in STING Affect Human Innate Immune Responses to Poxviruses
by: Richard B. Kennedy, et al.
Published: (2020-10-01)